The OncoSim microsimulation model (www.oncosim.ca), initiated by the Partnership in 2008, is a powerful microsimulation modelling tool based on real-world data that can address complex questions to improve patient outcomes and optimize cancer system resources.
Despite improvements in diagnosis and treatment over the past several decades, breast cancer remains the most common malignancy and the greatest cause of cancer deaths in women worldwide.
BACKGROUND: New therapeutics are urgently needed to improve the outcome of men with castrate-resistant prostate cancer (mCRPC), a leading cause of cancer-related deaths in Canadian men. Prostate-specific membrane antigen (PSMA) is a known biomarker and therapeutic target for prostate cancer.
Due to the site of the cancer, head and neck cancer (HNCa) survivors face unique challenges and serious health care issues akin to chronic disease as a result of their diagnosis and treatment; yet, the long-term needs of HNCa survivors are not well understood.
Oral cancer is an important global health problem. The disease has a high mortality rate (~63% 5-year survival) mainly due to the advanced stage at which it is diagnosed. In Canada, oral cancer is the ninth most common cancer affecting about 4700 people a year, while in some are
At the core of the BC OCPP is the OCPL, a globally unique study that follows patients identified with precancer over time with the objective to evaluate clonal/molecular approaches to create an integrated plan for oral dysplasia/cancer assessment and management that is rapid and cost-effective.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.